LY-334370 is a selective serotonin 5-HT1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals.
LY-334370 is a selective serotonin 5-HT1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals.
Source: Wikipedia "LY-334370" · CC BY-SA 4.0
Share this article: X · Bluesky